Cipla’s 1QFY19 revenues (Rs39,390mn) and net earnings (Rs4,510mn) were above consensus estimates led by an one-time extraordinary contingent payment of Rs 850mn (Chase Pharma Divestment) reported as other income.
Net Sales and PAT of the company are expected to grow at a CAGR of 8% and 6% over 2016 to 2019E respectively.Hence, we say that, we are Overweight in this particular scrip for Medium to Long term investment.
This is neither an offer nor a solicitation to purchase or sell securities. The information and views contained on this site are believed to be reliable, but no responsibility (or liability) is accepted for errors of fact or opinion. Writers and contributors may be trading in, or have positions in the securities mentioned in their articles. Neither IndiaNotes nor any of the contributors accepts any liability arising out of use of the above information/article. Reproduction in whole or in part without written permission is prohibited.